Uncover HIMS stock price moves, earnings beats, technical analysis, and 2026 forecast. Is HIMS stock a buy? Explore valuation, risks, and analyst views today.
Introduction
Hims & Hers Health Inc. (HIMS stock) connects patients to telehealth for wellness needs. It offers treatments for hair loss, skin care, and sexual health online.
Investors watch HIMS stock closely after volatile trading in early 2026. Subscriber growth draws attention amid rising telehealth demand. Tech-health stocks face regulatory and economic headwinds.
Latest stock Price & Trend
HIMS stock closed at $15.74 on March 6, 2026, using last market close data. It dropped 0.88% that day, with a range of $15.21 to $15.84. Volume hit 14.4 million shares.
The 5-day trend fell 4.5% amid profit-taking after February peaks. One-month view shows pullback from $27 highs. Three-month down from $33 in January; six-month mixed.
Year-to-date decline steepened after early gains. 52-week high reached $70.43; low $13.74. Overall trend turned bearish short-term, signaling caution for momentum chasers but opportunity near lows.
Technical Analysis
Support levels near $15.21, where recent lows drew buyers. Resistance at $16.50 blocks upside. These levels act as price floors and ceilings, guiding buy or sell decisions.
RSI sits neutral around 45, avoiding overbought zones post-rally. MACD trend bearish with downward crossover. 50-day moving average above 200-day shows no death cross yet.
Volume spiked to 32 million on up days earlier, now cooling. High beta of 2.61 means sharp swings. Beginners use these to spot entry points safely.
Analyst Ratings & Price Targets
Thirteen analysts rate HIMS stock Hold: specific Buy/Hold/Sell counts lean neutral. Average price target $26.38, up 67.6% from $15.74. Highs near $32; lows lower.
No major upgrades recent from firms like Goldman. Consensus Hold means steady growth expected, not explosive. Investors gain from balanced Wall Street views.
Insider Activity
Insider selling noted in past quarters, but recent data quiet. No standout large buys or sells flagged. Management holds steady amid volatility.
This implies measured confidence, not alarm. Watch for shifts signaling caution.
Valuation Analysis
Trailing P/E at 60.36 reflects profitability shift. Forward P/E attractive on growth. Price-to-sales reasonable at $10.65B market cap over $1.48B revenue.
Revenue up sharply YoY to $1.48B; EPS at $0.88. Net income $126M positive. Free cash flow improving; cash strong, debt low.
Peers like Teladoc trade at discounts. HIMS stock looks fairly valued, with growth justifying premium.
Recent Earnings & Catalysts
Latest quarters showed revenue beats on subscriber adds. EPS topped estimates at $0.88 TTM. Guidance optimistic for personalization push.
Catalysts include weight loss offerings and AI tools. Partnerships expand reach. Strong results lifted shares pre-pullback.
Bullish Case
Subscriber demand grows with wellness trends. Revenue catalysts from new categories like GLP-1 drugs. Tech platform scales efficiently.
Margins expand via direct-to-consumer model. Steady 67% upside to targets supports case.
Bearish Case
Competition rises from Ro, Amazon Clinic. Regulatory scrutiny on telehealth prescriptions. Margin pressures if growth slows.
Customer retention challenges in saturated markets. Economic dips cut discretionary spend.
Market Sentiment & Investor Psychology
Short interest data limited; options activity balanced. Institutional ownership up to key levels. Retail piled in on highs, now sidelined.
Fear & Greed neutral. Sentiment optimistic on fundamentals, fearful on volatility.
Short-Term Outlook
Overbought unwind via bearish MACD suggests consolidation. Volume drop points to range trading near $15-16. Momentum pause likely.
Medium to Long-Term Outlook
Telehealth model proves resilient. Industry expands 20% yearly. Finances solidify with profits.
Strong position favors accumulate on weakness for long-term holders.
FAQ
Is HIMS stock a buy right now?
Yes for growth investors; Hold rating fits caution.
What is the price target for HIMS stock?
Average $26.38, implying 67% upside.
What are major risks for HIMS stock?
Competition, regulation, subscriber churn.
HIMS earnings outlook?
Continued beats on revenue, EPS growth.
HIMS stock forecast 2026?
Targets $26+ if execution holds.
Suggestions
- Compare with Opendoor stock analysis.
- See our telehealth sector forecast.
- Read wellness tech valuation guide.
Conclusion
Buy HIMS stock on dips. Profitability and targets outweigh volatility risks. Growth story intact for patient investors.
Disclaimer: This article is for informational purposes only and not financial advice.